Search
Orchestra Biomed Holdings Inc
OBIOAdd to Watchlist
4.190USD
-0.110-2.56%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
245.66MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.56%
5 Days
-1.18%
1 Month
+5.01%
6 Months
-2.78%
Year to Date
+0.96%
1 Year
+44.98%
Key Figures
4.300Open
4.470High
252.84KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.43%Turnover Ratio
4.300Prev. Close
4.190Low
826.63KTurnover
LossP/E Static
5.96P/B
0.00%Div Yield TTM
-68.33%ROA
5.42452wk High
0.30Volume Ratio
-61.02MNet Profit
58.63MShares
-0.9479EPS TTM
0.51Beta
-189.00%ROE
2.20052wk Low
6.51%Amplitude
70.91%Gross Margin
245.66MMarket Cap
1.85Reward/Risk
4.19%Risk Rate
TradingKey Stock Score of Orchestra Biomed Holdings Inc
Currency: USD Updated: 2026-07-02Key Insights
Orchestra Biomed Holdings Inc's fundamentals are relatively healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 130 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.17.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Orchestra Biomed Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Orchestra Biomed Holdings Inc Highlights
StrengthsRisks
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1113.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.48M.
Undervalued
The company’s latest PE is -4.42, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.76M shares, increasing 8.04% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 94.56K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.09.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
12.167
Target Price
+182.95%
Upside Space
Orchestra Biomed Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Orchestra Biomed Holdings Inc Info
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Ticker SymbolOBIO
CompanyOrchestra Biomed Holdings Inc
CEOHochman (David P)
Website
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Orchestra Biomed Holdings Inc (OBIO)?
The current price of Orchestra Biomed Holdings Inc (OBIO) is 4.19.
What is the symbol of Orchestra Biomed Holdings Inc?
The ticker symbol of Orchestra Biomed Holdings Inc is OBIO.
What is the 52-week high of Orchestra Biomed Holdings Inc?
The 52-week high of Orchestra Biomed Holdings Inc is 5.42.
What is the 52-week low of Orchestra Biomed Holdings Inc?
The 52-week low of Orchestra Biomed Holdings Inc is 2.20.
What is the market capitalization of Orchestra Biomed Holdings Inc?
The market capitalization of Orchestra Biomed Holdings Inc is 245.66M.
Is Orchestra Biomed Holdings Inc (OBIO) currently rated as Buy, Hold, or Sell?
According to analysts, Orchestra Biomed Holdings Inc (OBIO) has an overall rating of Buy, with a price target of 12.17.
What is the Earnings Per Share (EPS TTM) of Orchestra Biomed Holdings Inc (OBIO)?
The Earnings Per Share (EPS TTM) of Orchestra Biomed Holdings Inc (OBIO) is -1.11.